ClinicalTrials.gg
CompletedNCT03533478Updated May 22, 2019

Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema

A Phase 2 interventional study of Oral treatment Alzer y Diamel and Placebo in Diabetic Macular Edema, sponsored by Catalysis SL. Completed at 1 site in Cuba. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-22.

Sponsored by Catalysis SL · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Mar 2015, registered May 2018).
Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Macular edema is the main cause of low vision in diabetics. They continue looking for new treatment alternatives. The nutritional supplement Alzer, is a powerful antioxidant that together with Diamel, a supplement that has shown efficacy in metabolic control, could be a therapeutic option. Objective: To evaluate the therapeutic efficacy of the Alzer Diamel combination in mild and moderate macular edema. Material and method: A randomized double-blind phase II clinical trial versus placebo will be conducted in 64 patients, who will be randomly assigned to two groups, one will receive Alzer + Diamel and another will receive placebo from Alzer and Diamel. All patients will undergo clinical, biochemical and ophthalmological evaluation during the study.

02

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Nutritional supplement
  • Diabetic Macular Edema
  • Diabetes
  • Alzer
  • Oxidative Stress
  • Diamel
03

In context

Diabetes Mellitus

8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.

This study's enrollment of 64 is below the median of 80 across 6,023 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Catalysis SL is the lead sponsor of 53 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetics type 2 insulin treated.
  • Age between 18 and 65 years.
  • Glycosylated (HB A1c) \<8% at the beginning of the investigation.
  • Patients who express written voluntariness to enter the study with their signature of the document.
  • If woman of childbearing age, negative pregnancy test and use of barrier .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and lactation.
  • Age over 65 years.
  • Macular edema with vitreous-retinal traction or other cause (renal, arterial hypertension, post-surgical).
  • Opacity of the refractive media that hinders the ophthalmological examination.
  • History of to another similar product or one of its components.
  • Patients at potential risk of not compliance the study (those who will travel during the period of the investigation or distance in their residence, outside the city).
  • Subjects who are participating in another clinical trial Patients with cognitive disorders or a mental disorder that hinders their follow-up.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Group I

    32 patients with mild or moderate diabetic macular edema.

    Dietary Supplement: Oral treatment Alzer y Diamel

  • Placebo comparator
    Group II

    32 patients with mild or moderate diabetic macular edema

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementOral treatment Alzer y Diamel

    Alzer: Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year. Diamel: Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year.

  • Dietary supplementPlacebo

    Placebo treatment

06

What researchers measure

Primary outcomes

  1. Macular retinal thickness

    macular retinal measure

    Time frame: 1 year

Secondary outcomes

  1. Visual acuity

    visual acuity test

    Time frame: 1 year

07

Study locations

1 site
  • National Institute of Endocrinology
    Vedado, Havana 10400, Cuba
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03533478
Lead sponsor
Catalysis SL
Responsible party
Sponsor
First posted
May 23, 2018
Start date
Mar 1, 2015
Primary completion
Dec 1, 2018
Completion
Dec 30, 2018
Last update
May 22, 2019

Study contacts

Juana Elvira Maciques Rodríguez, Dr.
principal investigator · National Institute of Endocrinology, Cuba

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion